Key result
Mitophagy pathway regulation links to metabolic and oxidative stress in HFpEF, but causal data remain limited.
Why the study?
Mitochondrial dysfunction has been proposed as a link between cardiometabolic stress, systemic inflammation, and cardiac remodeling in HFpEF, directing attention to mitophagy as a mechanism of mitochondrial quality control. However, evidence from human myocardium remains limited, and discrepancies with animal models restrict the direct translation of mechanistic findings.
This narrative review highlights the potential role of mitophagy pathways in HFpEF pathophysiology, noting that while experimental studies link impaired mitochondrial turnover to cardiomyocyte dysfunction, human myocardial evidence remains limited.
Answers are grounded in this paper and cite their sources.
Preclinical mitophagy data in HFpEF leave clinical relevance open; human mechanistic studies required before therapeutic targeting.
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome characterized by cardiometabolic stress, impaired myocardial relaxation, and systemic inflammation. Mitochondrial dysfunction has been proposed as a link between these disturbances and cardiac remodeling, directing attention to mitophagy as a mechanism of mitochondrial quality control. This narrative review examines the PINK1/Parkin and receptor-mediated mitophagy pathways, their regulation by AMPK-mTOR and related stress-responsive signaling, and their potential interactions with metabolic dysregulation, oxidative stress, inflammation, and impaired nitric oxide-cGMP signaling in HFpEF. Experimental studies indicate that failure of mitochondrial turnover may aggravate oxidative injury and cardiomyocyte dysfunction, although mitophagy may also exert protective effects depending on disease stage and cellular context. Evidence from human myocardium, however, remains limited. Recent metabolomic and single-cell studies have identified distinct metabolic and cellular alterations in HFpEF, yet they do not establish changes in mitophagic flux or demonstrate causality. In addition, discrepancies between the human myocardial phenotype and commonly used animal models restrict the direct translation of mechanistic findings. Emerging therapies, including sodium-glucose cotransporter 2 inhibitors and mitochondria-targeted interventions, highlight the therapeutic relevance of metabolic and mitochondrial function, although whether their benefits involve mitophagy is not yet known. Further studies employing dynamic measurements of mitophagic flux, tissue-specific interventions, and direct comparisons across heart failure phenotypes are warranted to determine whether mitophagy dysregulation represents a causal contributor, a compensatory response, or a shared consequence of disease.
No takes yet. Share an insight, caveat, or question.
Bu et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Mitophagy pathways (PINK1/Parkin and receptor-mediated) and mitochondria-targeted interventions was evaluated. Mitophagy regulation via PINK1/Parkin and receptor-mediated pathways is linked to metabolic and oxidative stress in HFpEF, though direct human causal evidence remains limited.
Synapse has enriched 10 related papers. Consider them for comparative context: